A tricyclic antidepressant
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Lofepramine

Item No. 20813

Technical Information
Formal Name
1-(4-chlorophenyl)-2-[[3-(10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)propyl]methylamino]-ethanone
CAS Number
23047-25-8
Synonyms
  • Lopramine
Molecular Formula
C26H27ClN2O
Formula Weight
Purity
≥95%
Formulation
A crystalline solid
DMF: 10 mg/mlDMF:PBS (pH 7.2)(1:3): 0.25 mg/mlDMSO: 3 mg/ml
λmax
251 nm
SMILES
CN(CC(C1=CC=C(Cl)C=C1)=O)CCCN2C3=C(C=CC=C3)CCC4=C2C=CC=C4
InChi Code
InChI=1S/C26H27ClN2O/c1-28(19-26(30)22-13-15-23(27)16-14-22)17-6-18-29-24-9-4-2-7-20(24)11-12-21-8-3-5-10-25(21)29/h2-5,7-10,13-16H,6,11-12,17-19H2,1H3
InChi Key
SAPNXPWPAUFAJU-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Wet ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Add

    Add

    Add

    Product Description

    Lofepramine is a first generation tricyclic antidepressant that is extensively metabolized to desipramine.1 It potently inhibits serotonin and norepinephrine transporters (Kds = 70 and 5.4 nM, respectively) and less potently antagonizes serotonin, histamine, and muscarinic receptors.2,3,4

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Lancaster, S.G., and Gonzalez, J.P. Lofepramine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 37(2), 123-140 (1989).

    2. Tatsumi, M., Groshan, K., Blakely, R.D., et alPharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur. J. Pharmacol. 340(2-3), 249-258 (1997).

    3. Cusack, B., Nelson, A., and Richelson, E. Binding of antidepressants to human brain receptors: Focus on newer generation compounds. Psychopharmacology (Berl.) 114(4), 559-565 (1994).

    4. Stanton, T., Bolden-Watson, C., Cusack, B., et alAntagonism of the five cloned human muscarinic cholinergic receptors expressed in CHO-K1 cells by antidepressants and antihistaminics. Biochem. Pharmacol. 45(11), 2352-2354 (1993).